Closed-Loop Neurostimulation for Biomarker-Driven, Personalized Treatment of Major Depressive Disorder
July 7th, 2023
Deep brain stimulation triggered by a patient-specific neural biomarker of a high-symptom state may better control symptoms of major depressive disorder compared to continuous, open-loop stimulation. This protocol provides a workflow for identifying a patient-specific neural biomarker and controlling the delivery of therapeutic stimulation based on the identified biomarker.
We are assessing the therapeutic benefit of closed-loop personalized deep brain stimulation for the treatment of major depressive disorder. This protocol outlines how to identify a personalized neural biomarker that is correlated with symptom severity, and then program an implanted neurostimulator to administer stimulation using that biomarker. Prior applications of deep brain stimulation for depression used continuous stimulation, which was always on, regardless of symptom status.
This protocol describes using closed-loop stimulation in which we only deliver stimulation during high symptom states. Continued work to identify biomarkers for control of closed-loop stimulation will facilitate an approach where we can target the unique time courses of different symptoms.
View the full transcript and gain access to thousands of scientific videos
Overview
This study evaluates the therapeutic efficacy of closed-loop personalized deep brain stimulation (DBS) for major depressive disorder (MDD). A workflow is provided for identifying individual neural biomarkers correlated with symptom severity to tailor stimulation delivery, as opposed to the conventional continuous stimulation approach.
Key Study Components
Area of Science
- Neuroscience
- Psychiatry
- Neurotechnology
Background
- Major depressive disorder often requires innovative treatment approaches.
- Deep brain stimulation has been used for depression but typically employs continuous delivery.
- Closed-loop systems adapt to the patient's symptomatology.
- Identifying a personal neural biomarker may enhance treatment efficacy.
Purpose of Study
- To assess the benefits of personalized closed-loop DBS for MDD.
- To establish a protocol for identifying patient-specific neural biomarkers.
- To administer stimulation based solely on high symptom states.
Methods Used
- Closed-loop deep brain stimulation system.
- Patient-specific neural biomarker identification and programming of neurostimulators.
- Focus on delivering stimulation during elevated symptom periods.
- Assessment of symptom severity to guide stimulation delivery.
Main Results
- Closed-loop DBS may improve MDD symptom control compared to continuous stimulation.
- Personalized biomarkers facilitate targeted stimulation during critical periods.
- Potential for optimizing therapy based on individual symptom patterns.
- Highlights the capacity to adapt treatments dynamically based on real-time data.
Conclusions
- The study demonstrates a more effective approach to DBS for MDD via personalized biomarker-driven stimulation.
- This methodology promises better alignment of therapeutic interventions with patient needs.
- Impacts understanding of symptom management in neuropsychiatric disorders.
Frequently Asked Questions
Executive Industry Relevance
Closed-loop neurostimulation for major depressive disorder (MDD) introduces a biomarker-driven paradigm that enables real-time, patient-specific intervention. This approach addresses the challenge of symptom variability and therapeutic habituation, offering predictive confidence at the intersection of neuroscience and personalized medicine. By aligning stimulation delivery with high-symptom states, the workflow supports risk-adjusted advancement and portfolio differentiation in neuropsychiatric device development.
Strategic Applications in Biopharma R&D
Early Discovery & Target Validation
- Enables interrogation of neural circuit mechanisms underlying depressive symptom states.
- Supports functional target validation by linking neural biomarkers to clinical symptomatology.
- Facilitates mechanistic de-risking through state-space modeling of symptom-neural feature relationships.
Screening & Assay Development
- Establishes validated neural biomarkers as quantitative readouts for device programming.
- Standardizes symptom-linked neural feature detection for reproducible stimulation protocols.
- Prepares a scalable framework for screening candidate biomarkers across patient populations.
Translational & Preclinical Research
- Aligns neural biomarker identification with translational biomarker strategies for neuropsychiatric disorders.
- Enables continuity from discovery of neural correlates to preclinical and clinical device validation.
- Supports risk-adjusted decisions by quantifying biomarker-driven therapeutic response.
Pipeline & Workflow Integration
This closed-loop neurostimulation workflow bridges early discovery, biomarker validation, and translational device programming for MDD.
- Discovery Biology: Integrates patient symptom reports with neural recordings to clarify mechanistic pathways.
- Screening: Provides quantitative neural features for reproducible device calibration and assay readiness.
- Analytics: Utilizes state-space modeling to differentiate symptom states and guide stimulation triggers.
- Translational Research: Connects biomarker-driven device programming to preclinical and clinical endpoints.
- Enterprise Reuse: Establishes a reusable platform for biomarker-driven neuromodulation across neuropsychiatric indications.
Operational & Enterprise Impact
- Scientific Value: Increases predictive confidence in target engagement and symptom modulation.
- Operational Value: Standardizes biomarker identification and device programming for scalable deployment.
- Strategic Value: Enables data-driven go/no-go decisions and reduces late-stage biological risk.
- Portfolio Impact: Supports risk-adjusted prioritization of neuromodulation assets for psychiatric disorders.
Implementation Considerations
- Requires expertise in neurophysiology, computational modeling, and device programming.
- Demands access to chronically implanted neurostimulation systems and neural recording infrastructure.
- Necessitates cross-team standardization of symptom reporting and neural data analysis.
- Adaptation across patient populations may require individualized biomarker discovery workflows.
- Dependent on robust state-space modeling to ensure reliable symptom state differentiation.
